AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
NCT ID: NCT06507150
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
140 participants
INTERVENTIONAL
2024-09-01
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Smartphone Based Digital Application in Improving Headache Related Parameters in Patients With Migraine
NCT04984720
Sphenopalatine Ganglion Blockade in Migraine
NCT05210192
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188
Rate , Predictors and Outcome of Chronic Migraine
NCT05079659
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
NCT03083860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Artificial Intelligence (AI) may advance migraine management by improving diagnosis, prediction, and educational outreach. AI applications are currently being employed in diagnosing migraines more accurately by analyzing comprehensive patient data, thus differentiating migraine from other types of headaches. Additionally, AI algorithms predict migraine episodes, enabling preemptive measures. They also streamline medication management through reminders and monitor patient adherence, which is crucial for preventing medication overuse and optimizing treatment outcomes.
Moreover, AI can bridge the educational gap in migraine understanding. By using adaptive learning technologies, AI platforms can deliver personalized educational content, tailored to an individual's knowledge level and learning pace, enhancing understanding and engagement. This approach not only facilitates better management of the condition but also promotes a broader societal awareness essential for destigmatizing migraine.
The primary objective of this study is to ascertain if the addition of AI-assisted migraine education to standard migraine education yields a superior improvement in the patients' understanding of their condition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AIME - AI-assisted migraine education
Intervention group: it receives AI-assisted migraine education in addition to standard migraine education
AI-assisted migraine education (AIME)
AIME Group will undergo the established migraine education plus AI-assisted education.
SME -Standard Migraine Education
Control group: it receives standard migraine education only
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AI-assisted migraine education (AIME)
AIME Group will undergo the established migraine education plus AI-assisted education.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosis of migraine, confirmed through the medical chart
* The participant must be capable of giving signed informed consent
* Access to a laptop, computer, smartphone, or tablet
Exclusion Criteria
* Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study.
* Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ente Ospedaliero Cantonale, Bellinzona
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chiara Zecca
Prof, dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ente Ospedaliero Cantonale - Ospedale Regionale di Lugano
Lugano, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOC.NSI.HA.2401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.